Jolynn Tumolo

A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.

The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular subtype-guided treatment of metastases, according to a research team from Weill Cornell Medicine, New York, New York.

Breckenridge Pharmaceutical Inc. is recalling 7107 bottles of duloxetine delayed-release capsules because of an N-nitroso duloxetine impurity, according to the October 23, 2024, US Food and Drug Administration (FDA) Enforcement Report. The recall follows a similar recall the firm initiated for the drug earlier this year.

Nearly 2000 bottles of atovaquone oral suspension distributed by Bionpharma Inc. are under a Class I recall for contamination with Cohnella bacteria, according to the October 23, 2024, US Food and Drug Administration (FDA) Enforcement Report.

Accord Healthcare Inc. is recalling 11 214 vials of cisplatin injection after samples failed to meet impurity/degradation specifications during testing, according to the October 23, 2024, US Food and Drug Administration (FDA) Enforcement Report.

| BOSTON—Eight of 11 patients with hereditary angioedema treated with 50 mg of the investigational gene editing therapy NTLA-2002 achieved

Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the InternationalJournal of Cerebrovascular Disease and Stroke.

BOSTON—Oral sebetralstat does not significantly differ in time to symptom relief from intravenous recombinant human C1 esterase inhibitor (IV-rhC1-INH) for

A median 6 years after treatment with elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD), 94% of patients showed no decline in neurological functioning and 81% remained free of major functional disabilities. Nevertheless, reports of hematologic malignancies in some patients have raised concern, according to a pair of studies published in the New England Journal of Medicine.

Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with major depressive disorder (MDD) with inadequate response to previous antidepressant therapy, according to a poster presentation at Psych Congress.